AABB

    FDA Issues EUA for COVID-19 Convalescent Plasma; AABB Toolkit Now Available

    The Food and Drug Administration has issued an emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) as a treatment for patients battling COVID-19. AABB has developed a new toolkit for CCP under FDA’s EUA to assist members in keeping updated on the changing regulatory environment regarding CCP. AABB will update the toolkit based on additional updates. 

    Recent Stories
    AABB Releases 2020 Billing Guide as Complimentary Benefit

    Big Data Is Focus of Latest Issue of AABB News

    FDA Issues EUA for COVID-19 Convalescent Plasma; AABB Toolkit Now Available